Abstract
Background and purpose Osteoradionecrosis (ORN) of the mandible represents a severe, debilitating complication of radiation therapy (RT) for head and neck cancer (HNC). At present, no Normal Tissue Complication Probability (NTCP) models for risk of ORN exist. The aim of this study was to develop a multivariable clinical/dose-based NTCP model for the prediction of ORN any grade (ORNI-IV) and Grade IV (ORNIV) following radiotherapy (± chemotherapy) in HNC patients.
Methods Included HNC patients were treated with (chemo-)radiotherapy between 2005 and 2015. Mandible bone radiation dose-volume parameters, and clinical variables (i.e. age, sex, tumor site, pre-RT dental extractions, chemotherapy history, post-operative RT and smoking status), were considered as potential predictors. The patient cohort was randomly divided into a training (70%) and independent test (30%) cohort. Bootstrapped forward variable selection was performed in the training cohort to select the predictors for the NTCP models. Final NTCP model(s) were validated on the holdback test subset.
Results Of 1259 included HNC patients, 13.7% (n=173 patients) developed any grade ORN (ORNII-IV primary endpoint) and 5% (n=65) ORNIV (secondary endpoint). All dose and volume parameters of the mandible bone were significantly associated with the development of ORN in univariable models. Multivariable analyses identified D30% and pre-RT dental extraction as independent predictors for both ORNI-IV and ORNIV best-performing NTCP models with an AUC of 0.78 (AUCvalidation=0.75) and 0.81 (AUCvalidation=0.82), respectively.
Conclusion This study presented NTCP models – based on mandible bone D30% and pre-RT dental extraction – that predict ORNI-IV and ORNIV (i.e. needing invasive surgical intervention) following HNC radiotherapy. Our results suggest that less than 30% of the mandible should receive a dose of 35Gy or more for an ORNI-IV risk lower than 5%. These NTCP models can improve ORN prevention and management by identifying patients at risk of ORN.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. van Dijk, received/receives funding and salary support from the Dutch organization NWO ZonMw during the period of study execution via the Rubicon Individual career development grant.
Drs. Mohamed and Abusaif are funded for this work by The University of Texas MD Anderson Cancer Center-Oropharynx Cancer Program generously supported by Mr. and Mrs. Charles W. Stiefel.
Dr. Hutcheson, Mohamed, Lai, and Fuller received/receives funding and salary support related to this project during the period of study execution from: the NIH National Cancer Institute (NCI) Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (R01CA218148).
Dr. Lai, Mohamed, and Fuller received/receives funding and salary support related to this project during the period of study execution from: the National Institutes of Health (NIH) National Institute for Dental and Craniofacial Research (NIDCR) Establishing Outcome Measures Award (R01DE025248/R56DE025248).
Dr. Fuller received funding unrelated to this project during the period of study execution from NIH/NCI Cancer Center (P30CA016672, P50 CA097007, and R01CA2148250); from NIH/NIBIB (R25EB025787-01); from NIH/NSF (NSF1557679); NSF-CMMI grant (NSF1933369); and the Sabin Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MD Anderson Cancer Centers Institutional Review Board gave approval for the retrospective collection of imaging, dose and clinical information of head and neck cancer patients at MD Anderson Cancer Center [RCR03-0800]
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.